{"id":"NCT02669758","sponsor":"Alkermes, Inc.","briefTitle":"A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia","officialTitle":"A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-01-20","primaryCompletion":"2018-06-29","completion":"2018-06-29","firstPosted":"2016-02-01","resultsPosted":"2019-07-09","lastUpdate":"2019-07-26"},"enrollment":281,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"ALKS 3831","otherNames":[]}],"arms":[{"label":"ALKS 3831","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the long term safety and tolerability of ALKS 3831 in subjects with schizophrenia.","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AEs)","timeFrame":"Up to 52 weeks","effectByArm":[{"arm":"ALKS 3831","deltaMin":136,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":31,"countries":["United States","Bulgaria","Serbia","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":277},"commonTop":["Weight increased","Somnolence","Headache","Nasopharyngitis","Extra dose administered"]}}